Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza (Q30424161)

21 June 2017

1 reference

title

Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza (English)

1 reference

21 June 2017

0 references

4

Rino Rappuoli

1 reference

21 June 2017

Giuseppe Del Giudice

1

1 reference

21 June 2017

Elena Fragapane

series ordinal

2

1 reference

21 June 2017

Giovanni Della Cioppa

series ordinal

3

1 reference

21 June 2017

language of work or name

English

0 references

publication date

29 November 2012

1 reference

Expert Opinion on Biological Therapy

21 June 2017

1 reference

21 June 2017

13

1 reference

21 June 2017

1

1 reference

21 June 2017

121-135

1 reference

The evolution of H5N1 influenza viruses in ducks in southern China

21 June 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Airborne transmission of influenza A/H5N1 virus between ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Emerging respiratory viruses: challenges and vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Vaccinate before the next pandemic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

21 January 2018

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

T-cell immunosenescence: lessons learned from mouse models of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Systematic review of clinical and epidemiological features of the pandemic influenza A (H1N1) 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Rapid generation of pandemic influenza virus vaccine candidate strains using synthetic DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Influenza: options to improve pandemic preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Emergence of fatal avian influenza in New England harbor seals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.748030

10.1517/14712598.2013.748030

21 January 2018

Identifiers

DOI

1 reference

21 June 2017

1 reference